Voyager Therapeutics (VYGR) closed at $1.87 on November 6, 2026, up 8.4% from the previous close, on volume of 846,460 shares (30-day average 919,880).
Data as of November 6, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Voyager Therapeutics GAAP EPS of -$0.40 beats by $0.02, revenue of $4.01M misses by $2.34M
Seeking Alpha News (Thu, 5-Nov 5:22 PM ET)
Voyager Reports Third Quarter 2026 Financial and Operating Results
Globe Newswire (Thu, 5-Nov 4:01 PM ET)
H.C. Wainwright Sticks to Their Buy Rating for Voyager Therapeutics (VYGR)
TipRanks (Thu, 5-Nov 6:36 AM ET)
Globe Newswire (Tue, 27-Oct 8:01 AM ET)
Voyager Announces CEO Succession Plan, Appoints Robin Swartz President
Globe Newswire (Wed, 21-Oct 8:01 AM ET)
Voyager to Present at Upcoming Investor Conferences
Globe Newswire (Tue, 1-Sep 8:00 AM ET)
Market Chameleon (Thu, 14-May 6:44 AM ET)
Voyager’s Clinical Pipeline Expands Amid Strong Cash Position and Strategic Partnerships
Market Chameleon (Tue, 10-Mar 7:16 AM ET)
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
Voyager Therapeutics trades on the NASDAQ stock market under the symbol VYGR.
As of November 9, 2026, VYGR stock price climbed to $1.97 with 276,637 million shares trading.
VYGR has a beta of 1.20, meaning it tends to be more sensitive to market movements. VYGR has a correlation of 0.07 to the broad based SPY ETF.
VYGR has a market cap of $119.02 million. This is considered a Micro Cap stock.
Last quarter Voyager Therapeutics reported $4 million in Revenue and -$.40 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.02.
In the last 3 years, VYGR traded as high as $11.72 and as low as $1.68.
The top ETF exchange traded funds that VYGR belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
VYGR has underperformed the market in the last year with a return of -53.3%, while the SPY ETF gained +12.9%. In the last 3 month period, VYGR fell short of the market, returning -37.1%, while SPY returned -2.2%. However, in the most recent 2 weeks VYGR has outperformed the stock market by returning +13.2%, while SPY returned -1.4%.
VYGR support price is $1.77 and resistance is $1.96 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VYGR shares will trade within this expected range on the day.
